Plus:

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

First risk-sharing investment since VC’s takeout will position strategic entity Launch to advise Australian biotech as it navigates Phase III with up to $260M

Among a trio of clinical biotechs pricing IPOs ahead of Friday’s NASDAQ session, demand was highest for Praxis as the company posted a 46% gain, while the reception was more muted for Aligos

BioCentury's roundup of preclinical news

Highlights of weekly biotech stock moves